Claims for Patent: 10,493,150

Summary for Patent: 10,493,150

Title:	Nanoparticle complexes of paclitaxel, alemtuzumab, and albumin
Abstract:	Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	15/412,610
Patent Claims:	1. An antibody-albumin nanoparticle complex comprising albumin, a alemtuzumab antibody, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has CD52 binding specificity, wherein the complex has a diameter between 0.1 .mu.m and 1 .mu.m. 2. The antibody-albumin nanoparticle complex of claim 1, further comprising an alkylating agent. 3. The antibody-albumin nanoparticle complex of claim 2, wherein said alkylating agent is a platinum compound. 4. The antibody-albumin nanoparticle complex of claim 3, wherein said platinum compound is carboplatin. 5. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.9 .mu.m. 6. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.3 .mu.m. 7. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, wherein said antibody-albumin complexes comprise albumin, a alemtuzumab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have CD52 binding specificity, wherein the average diameter of at least 90 percent of said complexes is between 0.1 .mu.m and 1 .mu.m. 9. The pharmaceutical composition of claim 8, wherein said composition or said nanoparticle complexes comprise an alkylating agent. 10. The pharmaceutical composition of claim 9, wherein said alkylating agent is a platinum compound. 11. The pharmaceutical composition of claim 10, wherein said platinum compound is carboplatin. 12. The pharmaceutical composition of claim 8, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.9 .mu.m. 13. The pharmaceutical composition of claim 8, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.3 .mu.m. 14. The antibody-albumin nanoparticle complex of claim 8, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5. 15. The pharmaceutical composition of claim 8 which is formulated for injection. 16. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof. 17. A method of making an antibody-albumin nanoparticle complex, the method comprising mixing in vitro an aqueous albumin-paclitaxel nanoparticle with a alemtuzumab antibody under conditions to form the nanoparticle complex, wherein the complex has a diameter between 0.1 .mu.m and 1 .mu.m.

Details for Patent 10,493,150

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2032-10-01
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2032-10-01
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2032-10-01